美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Onestream Inc

27.51

-0.6300-2.24%

盤後：27.45-0.0600-0.22%19:35 EDT

成交量：133.84萬

成交額：3,687.71萬

市值：48.49億

市盈率：-15.57

高：28.11

開：27.84

低：27.16

收：28.14

資料載入中...

總覽公司新聞公告

Os Therapies Incorporated盤中異動股價大跌5.16%報1.75美元

Os Therapies Incorporated盤中異動早盤大幅跳水5.61%報1.85美元

Os Therapies Incorporated盤中異動早盤股價大漲5.69%

美國股市各時代具有代表性的股票

Os Therapies Incorporated盤中異動早盤大幅跳水6.63%

2025年ASCO中國之聲：突破耐藥、填補空白科倫博泰生物蘆康沙妥珠單抗展現EGFR突變非小細胞肺癌治療前景

每日经济新闻

全球首個！維立志博攻克0成藥腫瘤靶點，中國原研藥領跑國際

Os Therapies Incorporated盤中異動早盤股價大跌5.06%

艾伯維揮起拳頭

Os Therapies Incorporated盤中異動急速拉昇5.10%報1.61美元

科濟藥業舒瑞基奧侖賽注射液（CT041）的摘要已公佈於ASCO網站

Os Therapies Incorporated盤中異動股價大漲7.58%

Vaulta構建Web3銀行網絡，服務個人而非巨頭

Os Therapies Incorporated盤中異動臨近午盤股價大跌5.03%

Os Therapies Incorporated盤中異動早盤股價大跌6.10%

中國多中心研究探索奧雷巴替尼治療慢性期CML的優化劑量

Os Therapies Incorporated盤中異動早盤股價大跌5.27%報1.71美元

健訊Daily | 鄭州通報“健康證”辦理有關問題；中國醫藥擬3.02億元收購金穗科技100%股權

21世纪经济报道

Onestream, Inc.盤中異動下午盤股價大漲5.06%

Os Therapies Incorporated盤中異動股價大跌5.13%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":27.51,"timestamp":1749844800000,"preClose":28.14,"halted":0,"volume":1338419,"hourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.51,"latestTime":"19:35 EDT","volume":30730,"amount":843754.23,"timestamp":1749857751404},"delay":0,"floatShares":69821187,"shares":176260091,"eps":-1.766751,"marketStatus":"休市中","change":-0.63,"latestTime":"06-13 16:00:00 EDT","open":27.84,"high":28.11,"low":27.162,"amount":36877108.041222,"amplitude":0.033689,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.766751,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":28.14,"preHourTrading":{"tag":"盘前","latestPrice":27.56,"preClose":28.14,"latestTime":"09:18 EDT","volume":1399,"amount":39264.892201,"timestamp":1749820732001},"postHourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.51,"latestTime":"19:35 EDT","volume":30730,"amount":843754.23,"timestamp":1749857751404},"volumeRatio":1.099095181229347,"impliedVol":0.526,"impliedVolPercentile":0.3682},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":69821187,"roa":"-35.83%","roe":"-108.78%","lyrEps":-1.232998,"volumeRatio":1.099095181229347,"shares":176260091,"dividePrice":0,"high":28.11,"amplitude":0.033689,"preClose":28.14,"low":27.162,"week52Low":16.6942,"pbRate":"11.74","psRate":"9.41","week52High":35.39,"institutionHeld":0,"latestPrice":27.51,"eps":-1.766751,"divideRate":0,"volume":1338419,"delay":0,"ttmEps":-1.766751,"open":27.84,"prevYearClose":28.52,"prevWeekClose":28.92,"prevMonthClose":28.06,"prevQuarterClose":21.34,"fiveDayClose":28.92,"twentyDayClose":28.35,"sixtyDayClose":22.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543263323","title":"Os Therapies Incorporated盤中異動 股價大跌5.16%報1.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543263323","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543263323?lang=zh_tw&edition=fundamental","pubTime":"2025-06-13 22:40","pubTimestamp":1749825650,"startTime":"0","endTime":"0","summary":"北京时间2025年06月13日22时40分，Os Therapies Incorporated股票出现异动，股价快速跳水5.16%。截至发稿，该股报1.75美元/股，成交量8.7732万股，换手率0.31%，振幅6.52%。Os Therapies Incorporated股票所在的生物技术行业中，整体跌幅为0.49%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613224050977e5aa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613224050977e5aa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","OS","BK4139","BK4097"],"gpt_icon":0},{"id":"2542384995","title":"Os Therapies Incorporated盤中異動 早盤大幅跳水5.61%報1.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542384995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542384995?lang=zh_tw&edition=fundamental","pubTime":"2025-06-11 21:57","pubTimestamp":1749650258,"startTime":"0","endTime":"0","summary":"北京时间2025年06月11日21时57分，Os Therapies Incorporated股票出现波动，股价急速下跌5.61%。截至发稿，该股报1.85美元/股，成交量5.4093万股，换手率0.19%，振幅3.57%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.14%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506112157389517efa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506112157389517efa9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","OS","BK4139","BK4097"],"gpt_icon":0},{"id":"2542333711","title":"Os Therapies Incorporated盤中異動 早盤股價大漲5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542333711","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542333711?lang=zh_tw&edition=fundamental","pubTime":"2025-06-09 22:09","pubTimestamp":1749478199,"startTime":"0","endTime":"0","summary":"北京时间2025年06月09日22时09分，Os Therapies Incorporated股票出现波动，股价急速拉升5.69%。截至发稿，该股报1.77美元/股，成交量5.4583万股，换手率0.19%，振幅3.05%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.48%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609220959a700ba69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609220959a700ba69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","OS","BK4139","BK4097"],"gpt_icon":0},{"id":"2542385386","title":"美國股市各時代具有代表性的股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2542385386","media":"格上理财","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542385386?lang=zh_tw&edition=fundamental","pubTime":"2025-06-09 18:35","pubTimestamp":1749465300,"startTime":"0","endTime":"0","summary":"通过拥有矿石和运输资源，卡内基钢铁公司能够以较低的成本生产钢铁，并在竞争中胜出对手。拥有整个电信基础设施确保了全国范围内的兼容性和可靠性，这使得美国电话电报公司成为受监管的垄断企业。其结果是，苹果以不成比例的优势攫取了智能手机行业的利润，并对移动设备标准产生了全球影响。因此，特斯拉在电动汽车市场上具有显著的竞争优势，能够提供无缝、高效的电动汽车体验，而现有的电动汽车企业却很难做到这一点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/smjj/smdt/2025-06-09/doc-ineznnvh1191653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJTD4N35.SGD","IE","IE00BFSS7M15.SGD","LU0072461881.USD","LU0128525929.USD","LU0353189680.USD","LU1069347547.HKD","IE00BFSS8Q28.SGD","MACW.SI","BK4587","LU2250418816.HKD","USAW.SI","BK4511","IBM","LU1814569148.SGD","LU2106854487.HKD","LU0345768740.USD","LU0029864427.USD","LU0960925559.SGD","AAPL","LU2247934214.USD","LU2471134796.USD","SGXZ51526630.SGD","LU0312595415.SGD","LU2452424414.USD","LU2264538146.SGD","LU0095938881.EUR","IE0004086264.USD","OS","BK4602","BK4592","LU2089283258.USD","LU1861558580.USD","TSLL","LU0265550946.USD","TSLA","TSYW.SI","LU1934455863.HKD","MSFT","SG9999017495.SGD","LU2506951875.HKD","BK4585","LU2054465674.USD","LU0476273544.USD","SGXZ99366536.SGD","LU1206713676.USD","LU0345769631.USD","LU0823434583.USD"],"gpt_icon":1},{"id":"2541665074","title":"Os Therapies Incorporated盤中異動 早盤大幅跳水6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541665074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541665074?lang=zh_tw&edition=fundamental","pubTime":"2025-06-05 23:19","pubTimestamp":1749136791,"startTime":"0","endTime":"0","summary":"北京时间2025年06月05日23时19分，Os Therapies Incorporated股票出现异动，股价急速下跌6.63%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Immatics N V C/Wts 01/07/2025 、Liminatus Pharma, Inc.涨幅较大，Scinai Immunotherapeutics Ltd、Nucana Plc、Eyenovia, Inc.较为活跃，换手率分别为1806.54%、568.56%、189.49%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Scinai Immunotherapeutics Ltd、Liminatus Pharma, Inc.，振幅分别为140.64%、126.98%、75.39%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605231951a6fbf27c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605231951a6fbf27c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OS","BK4097","OSTX"],"gpt_icon":0},{"id":"2540039959","title":"2025年ASCO中國之聲：突破耐藥、填補空白 科倫博泰生物蘆康沙妥珠單抗展現EGFR突變非小細胞肺癌治療前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2540039959","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540039959?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 14:12","pubTimestamp":1749017536,"startTime":"0","endTime":"0","summary":"科伦博泰生物（HK06990）股价再创新高，今日盘中触及363港元/股。消息面上，在近日举行的2025年美国临床肿瘤学会（ASCO）年会上，科伦博泰的TROP2ADC芦康沙妥珠单抗治疗EGFR突变晚期非小细胞肺癌（NSCLC）的多项研究数据重磅公布，其临床价值引发学界广泛关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506043421704414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506043421704414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","PFS","BK4195","BK4211","BK4097","ORR"],"gpt_icon":0},{"id":"2540007780","title":"全球首個！維立志博攻克0成藥腫瘤靶點，中國原研藥領跑國際","url":"https://stock-news.laohu8.com/highlight/detail?id=2540007780","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540007780?lang=zh_tw&edition=fundamental","pubTime":"2025-06-01 09:59","pubTimestamp":1748743157,"startTime":"0","endTime":"0","summary":"维立志博研发的抗PD-L1/4-1BB双抗LBL-024在2025年ASCO舞台再获突破性验证。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2263243","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4097","06978","BK1574","ORR","BK1161","OS"],"gpt_icon":0},{"id":"2539275624","title":"Os Therapies Incorporated盤中異動 早盤股價大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275624?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 22:23","pubTimestamp":1748615012,"startTime":"0","endTime":"0","summary":"北京时间2025年05月30日22时23分，Os Therapies Incorporated股票出现异动，股价快速下跌5.06%。截至发稿，该股报1.50美元/股，成交量1.6605万股，换手率0.06%，振幅4.43%。Os Therapies Incorporated股票所在的生物技术行业中，整体跌幅为3.85%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025053022233295085aea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025053022233295085aea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","BK4097","BK4139","OS"],"gpt_icon":0},{"id":"2538211551","title":"艾伯維揮起拳頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2538211551","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538211551?lang=zh_tw&edition=fundamental","pubTime":"2025-05-25 10:59","pubTimestamp":1748141979,"startTime":"0","endTime":"0","summary":"艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！表1.艾伯维免疫领域核心产品这一颓势直接拖累艾伯维2024年净利润下跌12.03%。表2.艾伯维肿瘤领域核心产品然而，随着百济神州的泽布替尼、阿斯利康的阿卡替尼等二代BTK抑制剂通过“头对头”试验证明更优疗效与安全性，伊布替尼市场份额被快速瓜分。02频繁动刀为了走出“泥潭”，艾伯维在肿瘤领域多次挥刀，转而瞄准自免与神经科学等赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","LU0234572021.USD","LU1244550221.USD","IE00BDGV0183.EUR","LU1244550577.SGD","LU2237443382.USD","IE00BVYPNV92.GBP","PFS","LU0203347892.USD","LU0949170772.SGD","IE00BGHQF631.EUR","LU0310800379.SGD","PROC","BK4139","LU1934455863.HKD","LU2112291526.USD","OS","IE0009355771.USD","IE00B3PB1722.GBP","LU1093756325.SGD","LU2237443895.HKD","LU0861579265.USD","LU1585245621.USD","LU2133065610.SGD","ORR","LU1551013425.SGD","SG9999003800.SGD","SG9999015952.SGD","LU0912757837.SGD","LU1983299246.USD","ABBV","LU0820561909.HKD","LU2087621335.USD","BK4566","SG9999015986.USD","IE00B19Z3B42.SGD","LU1162221912.USD","LU2129689605.HKD","LU0029864427.USD","BK4093","IBD","LU1244550494.USD","CF","SG9999015945.SGD","LU0122379950.USD","LU1989772923.USD","LU0965509101.SGD","IE00B4R5TH58.HKD","BK4097","LU0211327993.USD"],"gpt_icon":0},{"id":"2537153585","title":"Os Therapies Incorporated盤中異動 急速拉昇5.10%報1.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537153585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537153585?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 23:17","pubTimestamp":1748013455,"startTime":"0","endTime":"0","summary":"北京时间2025年05月23日23时17分，Os Therapies Incorporated股票出现异动，股价大幅上涨5.10%。截至发稿，该股报1.61美元/股，成交量6.3982万股，换手率0.23%，振幅6.54%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.00%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052323173597636406&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052323173597636406&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","OS","BK4097","BK4139"],"gpt_icon":0},{"id":"2537976421","title":"科濟藥業舒瑞基奧侖賽注射液（CT041）的摘要已公佈於ASCO網站","url":"https://stock-news.laohu8.com/highlight/detail?id=2537976421","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537976421?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 08:00","pubTimestamp":1747958400,"startTime":"0","endTime":"0","summary":"关于舒瑞基奥仑赛注射液舒瑞基奥仑赛注射液是一款潜在全球同类首创的、靶向Claudin18.2蛋白的自体CAR-T细胞治疗候选产品，用于治疗Claudin18.2阳性实体瘤，主要治疗胃癌/食管胃结合部腺癌及胰腺癌。2020年9月，舒瑞基奥仑赛注射液被美国FDA授予\"孤儿药\"认定用于治疗胃癌/食管胃结合部腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4694213_ZH94213_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE0031619046.USD","IE00B19Z4B17.USD","BK1161","BK4230","PFS","CAR","OS","BK1574","LU2065731478.USD","CRS","02171","IE00B66KJ199.SGD","TPC","BK1585","BK4022","SOC","BK4211","BK4213","BK4097","BK4195","IE00B7SZL793.SGD","BK4006","BK4129","BK1587"],"gpt_icon":0},{"id":"2537942839","title":"Os Therapies Incorporated盤中異動 股價大漲7.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537942839","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537942839?lang=zh_tw&edition=fundamental","pubTime":"2025-05-22 21:31","pubTimestamp":1747920663,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日21时31分，Os Therapies Incorporated股票出现异动，股价大幅上涨7.58%。截至发稿，该股报1.56美元/股，成交量1.2777万股，换手率0.05%，振幅2.41%。Os Therapies Incorporated股票所在的生物技术行业中，整体跌幅为0.26%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522213103a4885360&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522213103a4885360&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4139","OSTX","BK4097"],"gpt_icon":0},{"id":"2537629419","title":"Vaulta構建Web3銀行網絡，服務個人而非巨頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2537629419","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537629419?lang=zh_tw&edition=fundamental","pubTime":"2025-05-22 11:00","pubTimestamp":1747882800,"startTime":"0","endTime":"0","summary":"数据来源：TradingView诞生于老牌公链 EOS 基础上的 Vaulta，如今有了一个更明确的定位：打造面向全球用户的 Web3 银行业网络。自从 Vaulta 宣布转型以来，市场反应非常直接。这正是 Vaulta 和 Virgo 的共识：未来的银行，必须从合规开始做起，从支付场景真正服务现实世界。据预计，到 2029 年全球跨境汇款市场将突破 1 万亿美元，Vaulta + VirgoPay 的组合正是在为这片蓝海构建链上通道。与传统 Web3 项目不同，Vaulta 并未急于铺设技术模板，而是从真实世界","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/news/57967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_highlight","symbols":["OS","MSB","BK4097","BK4006"],"gpt_icon":0},{"id":"2536148641","title":"Os Therapies Incorporated盤中異動 臨近午盤股價大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536148641","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536148641?lang=zh_tw&edition=fundamental","pubTime":"2025-05-20 23:34","pubTimestamp":1747755263,"startTime":"0","endTime":"0","summary":"北京时间2025年05月20日23时34分，Os Therapies Incorporated股票出现波动，股价快速下跌5.03%。截至发稿，该股报1.51美元/股，成交量9.5047万股，换手率0.34%，振幅5.60%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.41%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520233423975fad5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520233423975fad5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRXS","BK4097","OSTX","BK4082","BK4139","OS"],"gpt_icon":0},{"id":"2536089680","title":"Os Therapies Incorporated盤中異動 早盤股價大跌6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536089680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536089680?lang=zh_tw&edition=fundamental","pubTime":"2025-05-19 21:55","pubTimestamp":1747662913,"startTime":"0","endTime":"0","summary":"北京时间2025年05月19日21时55分，Os Therapies Incorporated股票出现波动，股价快速下挫6.10%。Os Therapies Incorporated股票所在的生物技术行业中，整体跌幅为0.16%。其相关个股中，Protagenic Therapeutics Inc C/Wts 26/04/2026 、Protagenic Therapeutics, Inc.、Abpro Holdings, Inc涨幅较大，Polyrizon Ltd.、Protagenic Therapeutics, Inc.、Nucana Plc较为活跃，换手率分别为7843.83%、5124.94%、2167.00%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 26/04/2026 、Protagenic Therapeutics, Inc.、Brainstorm Cell Therapeutics Inc.，振幅分别为330.19%、67.33%、31.82%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519215513a6e4d64c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519215513a6e4d64c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","OS","BK4097","BK4139"],"gpt_icon":0},{"id":"2535538289","title":"中國多中心研究探索奧雷巴替尼治療慢性期CML的優化劑量","url":"https://stock-news.laohu8.com/highlight/detail?id=2535538289","media":"亿欧网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535538289?lang=zh_tw&edition=fundamental","pubTime":"2025-05-16 10:08","pubTimestamp":1747361330,"startTime":"0","endTime":"0","summary":"一项多中心回顾性研究通过倾向性评分匹配比较了奥雷巴替尼40mg隔日一次和30mg QOD起始剂量在慢性髓性白血病患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例。经过PSM调整后，两组基线协变量相似。相比之下，40mg QOD组在这些指标上的表现略低。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ky.jrj.com.cn/2025/05/16100850435864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["OS","PFS","BK4097","BK4077","PSM","CHR","BK4211","BK4195"],"gpt_icon":0},{"id":"2535827964","title":"Os Therapies Incorporated盤中異動 早盤股價大跌5.27%報1.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535827964?lang=zh_tw&edition=fundamental","pubTime":"2025-05-15 23:04","pubTimestamp":1747321494,"startTime":"0","endTime":"0","summary":"北京时间2025年05月15日23时04分，Os Therapies Incorporated股票出现波动，股价急速跳水5.27%。截至发稿，该股报1.71美元/股，成交量6.7694万股，换手率0.31%，振幅6.11%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.73%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515230454a47fbc60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515230454a47fbc60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4097","OS","OSTX","BK4139"],"gpt_icon":0},{"id":"2535423032","title":"健訊Daily | 鄭州通報“健康證”辦理有關問題；中國醫藥擬3.02億元收購金穗科技100%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2535423032","media":"21世纪经济报道","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535423032?lang=zh_tw&edition=fundamental","pubTime":"2025-05-14 07:58","pubTimestamp":1747180699,"startTime":"0","endTime":"0","summary":"政策动向国家药监局：全过程深化药品监管改革全方位筑牢药品安全底线5月13日，第36届医药经济信息发布会在广州召开。国家药监局副局长徐景和表示，要全面贯彻落实党的二十届三中全会精神，落实《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》，全过程深化药品监管改革、全方位筑牢药品安全底线、全链条支持产业高质量发展，为保护和促进公众健康作出更大贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505143403788212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505143403788212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4195","BK4211","HCC","BK4231","OS","PFS","CDE","BK4006","BK4080","ADC","BK4097","BK4017"],"gpt_icon":0},{"id":"2535478577","title":"Onestream, Inc.盤中異動 下午盤股價大漲5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535478577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535478577?lang=zh_tw&edition=fundamental","pubTime":"2025-05-13 03:12","pubTimestamp":1747077172,"startTime":"0","endTime":"0","summary":"北京时间2025年05月13日03时12分，Onestream, Inc.股票出现波动，股价大幅拉升5.06%。Onestream, Inc.股票所在的软件服务行业中，整体涨幅为1.93%。其相关个股中，淘屏、Microalgo, Inc.、Hub Cyber Security Ltd C/Wts 22/08/2025涨幅较大，Freight Technologies, Inc.、淘屏、Microalgo, Inc.较为活跃，换手率分别为2460.66%、2201.92%、175.06%，振幅较大的相关个股有淘屏、Next Technology Holding Inc.、Freight Technologies, Inc.，振幅分别为293.34%、99.58%、75.20%。Onestream, Inc.公司简介：OneStream Inc 是一个支持人工智能的可扩展软件平台，将核心财务功能和更广泛的运营数据和流程统一到一个平台上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051303125394f4bdc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051303125394f4bdc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2534274063","title":"Os Therapies Incorporated盤中異動 股價大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534274063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534274063?lang=zh_tw&edition=fundamental","pubTime":"2025-05-12 22:24","pubTimestamp":1747059869,"startTime":"0","endTime":"0","summary":"北京时间2025年05月12日22时24分，Os Therapies Incorporated股票出现波动，股价快速下挫5.13%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为3.17%。其相关个股中，Cytomx Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Nucana Plc、Cytomx Therapeutics, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为537.21%、94.10%、63.53%，振幅较大的相关个股有Cytomx Therapeutics, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Fortrea Holdings Inc.，振幅分别为57.09%、54.64%、43.58%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512222437a6dc5d47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512222437a6dc5d47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4097","BK4139","OSTX"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":80,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"盤後","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"盤後","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"盤後","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-06-13","current":-21.083062,"percent":0.688372,"low":-1655.61542,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"high":-14.493656,"avg":-366.615877,"sd":586.069132,"marketCap":4959958960},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960}],"updateTime":1750046130035}}}